dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Zapata-Cobo, Paula |
dc.contributor.author | Salvador-Martín, Sara |
dc.contributor.author | Velasco, Marta |
dc.contributor.author | Palomino Pérez, Laura María |
dc.contributor.author | Clemente, Susana |
dc.contributor.author | Segarra, Oscar |
dc.date.accessioned | 2023-08-23T07:16:24Z |
dc.date.available | 2023-08-23T07:16:24Z |
dc.date.issued | 2023-08 |
dc.identifier.citation | Zapata-Cobo P, Salvador-Martín S, Velasco M, Palomino LM, Clemente S, Segarra O, et al. Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children. Pharmacol Res. 2023 Aug;194:106859. |
dc.identifier.issn | 1043-6618 |
dc.identifier.uri | https://hdl.handle.net/11351/10128 |
dc.description | Malaltia de Crohn; Polimorfisme; Pediatria |
dc.description.sponsorship | This research was funded by Instituto de Salud Carlos III, grant number PI19/00792 and PI22/00584 (L.L-F.), both cofunded by the European Union, by Instituto de Investigación Sanitaria Gregorio Marañón, grant number 2021-II-postdoc-01 (S.S-M.), and by Consejería de Educación, Universidades, Ciencia y Portavocía Comunidad de Madrid, grant number PEJ-2021-AI/BMD-21866 (P.Z-C.). |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | Pharmacological Research;194 |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Intestins - Inflamació - Tractament |
dc.subject | Factor de necrosi tumoral - Inhibidors - Ús terapèutic |
dc.subject.mesh | Inflammatory Bowel Diseases |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Tumor Necrosis Factors |
dc.subject.mesh | /antagonists & inhibitors |
dc.title | Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.phrs.2023.106859 |
dc.subject.decs | enfermedad inflamatoria intestinal |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | factores de necrosis tumoral |
dc.subject.decs | /antagonistas & inhibidores |
dc.relation.publishversion | https://doi.org/10.1016/j.phrs.2023.106859 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Zapata-Cobo P, Salvador-Martín S] Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain. [Velasco M, Palomino LM] Hospital Universitario Infantil Niño Jesús, Madrid, Spain. [Clemente S, Segarra O] Vall d’Hebron Hospital Universitari, Barcelona, Spain |
dc.identifier.pmid | 37473877 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |